黑龙江省乳腺癌HER2低表达临床病理诊断专家共识(2024版)

Expert consensus on clinicopathological diagnosis of breast cancer with low expression of HER2 in Heilongjiang province(2024 edition)

在过去的认知中,人类表皮生长因子受体2(Human epidermal growth factor receptor 2,HER2)低表达被认为对抗HER2靶向治疗无效。新型抗体缀合药物德曲妥珠单抗治疗HER2低表达乳腺癌疗效公布后,HER2低表达乳腺癌患者的诊疗选择成为乳腺肿瘤专家关注的热点。为规范HER2低表达乳腺癌的临床合理诊疗,黑龙江省医学会乳腺肿瘤学组参考国内外最新临床研究以及国内外专家共识,经我省专家组讨论后形成黑龙江省乳腺癌HER2低表达临床病理诊断专家共识,以指导临床医生对HER2低表达乳腺癌患者的诊疗决策,达到改善患者生存及预后的目的。该共识主要包括HER2低表达的定义和判读、HER2低表达结果的影响因素、HER2低表达检测的新方法、HER2低表达临床病理及分子生物学特性以及HER2低表达乳腺癌患者的临床诊疗指导,系统全面地展示了HER2低表达的临床病理诊断和治疗的共识。

In previous studies,low expression of human epidermal growth factor receptor 2(HER2)was considered ineffective against HER2-targeted therapy.After the announcement of the efficacy of new antibody conjugated drug,Detrastuzumab in the treatment of breast cancer with low expression of HER2,the diagnosis and treatment options of breast cancer patients with low expression of HER2 have become the focus of breast cancer experts.In order to standardize the clinical rational diagnosis and treatment of breast cancer with low expression of HER2,the Breast Oncology Group of Heilongjiang Medical Association,referring to the latest clinical research at home and abroad and the consensus of experts at home and abroad,formed the consensus of breast cancer with low expression of HER2 clinicopathological diagnosis experts after the discussion by the expert group in Heilongjiang province,to guide clinicians to make diagnosis and treatment decisions for breast cancer patients with low expression of HER2,so as to improve the survival and prognosis of patients.The consensus mainly includes the definition and interpretation of breast cancer with low expression of HER2,factors influencing the results of HER2 low expression,new detection methods,clinicopathological and molecular biological characteristics,and clinical diagnosis and treatment guidance for breast cancer patients with low expression of HER2,which systematically and comprehensively demonstrates the consensus of clinicopathological diagnosis and treatment for breast cancer with low expression of HER2.